Detail akcie Adicet Bio Rg online

Business Summary: Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Adicet Bio Inc revenues was not reported. Net loss decreased 2% to $86.3M. Lower net loss reflects Stock-based Compensation in SGA decrease of 57% to $4.1M (expense), Stock-based Compensation in R&D decrease of 49% to $4.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$16.32 to -$15.16.